NJ drugmaker faces civil, criminal fines over drug

March 5, 2013 by Linda A. Johnson

(AP)—A New Jersey-based generic drug maker has agreed to pay $45 million to resolve criminal and civil liability charges for improperly marketing its weight-gain drug to frail seniors.

Officials from Woodcliff Lake-based Par Pharmaceutical Cos. pleaded guilty to a charge of criminal misbranding Tuesday in federal court in Newark.

Par officials admitted they improperly marketed their Megace ES drug for treating anorexia and malnutrition in geriatric patients who did not have AIDS. It's approved for helping .

The company has also agreed to enter into a five-year corporate integrity agreement with and to drop a lawsuit it filed against the U.S. government.

Par agreed in July to be acquired by an affiliate of the private investment firm TPG for $1.84 billion.

Explore further: Merck will pay $950M to settle Vioxx investigation


Related Stories

Report: J&J will pay $2.2B in Risperdal settlement

July 20, 2012

(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Recommended for you

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.